- Basilea Pharmaceutica AG press release ( OTC:BPMUF ): FY GAAP EPS of CHF 1.02.
- Revenue of CHF 147.8M (-0.2% Y/Y).
- In 2022, a positive net cash flow of CHF 7.1M was provided by operating activities.
- Cash and cash equivalents, restricted cash and short-term investments amounted to CHF 108.6M as of December 31, 2022, compared to CHF 150.0M as of December 31, 2021.
- Outlook: Basilea expects to remain profitable and generate positive cash flow from operating activities in 2023, based on further increasing revenue from Cresemba and Zevtera and an expected significant reduction in operating expenses in 2023 versus 2022. Basilea provides the following financial guidance for FY 2023, excluding the potential impact from any in-licensing transactions:
- Cresemba & Zevtera related revenue is expected to grow by 19% - 21% toCHF 145 – 148 million (FY 2022: CHF 122.3 million), reflecting the continued commercial success of Basilea’s marketed products.
- Operating profit is expected to increase to CHF 45 – 50 million (FY 2022: CHF 18.5 million) and net profit to CHF 36 – 41 million (FY 2022: CHF 12.1 million).
- The Company expects to continue reducing its debt level through the partial repayment of the senior secured loan in the amount of approximately CHF 37 million.
For further details see:
Basilea Pharmaceutica AG GAAP EPS of CHF 1.02, revenue of CHF 147.8M; initiates FY22 guidance